冠脉搭桥与支架置入治疗冠心病多支病变的预后评价(3)
综上所述,对于冠心病复杂冠脉病变的治疗,尽管PCI的地位在不断地提高,CABG仍是不可替代的方式,且远期预后优于PCI。
参考文献:
[1]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心血管病预防指南[J].中华心血管病杂志,2011,39(1):3-22.
[2]Levine GN,Bates ER,Blankenship JC,et al.2015 AHA ACC SCAI focused update on primary percutaneous coronary intervention for patients with ST elevation myocardial infarction[J].Circulation,2016,133: 1135-1147.
[3]付焕梅.心血管病危险因素与冠脉病变支数关系的分析[J].中国心血管病研究,2010,8(1):36-39.
, 百拇医药
[4]Lee C W,Ahn J M,Cavalcante R,et al.Coronary Artery Bypass Surgery Versus Drug-Eluting Stent Implantation for Left Main or Multivessel Coronary Artery Disease:A Meta-Analysis of Individual Patient Data[J].Jacc Cardiovascular Interventions,2016:2481-2489.
[5]Fanari Z,Weiss S A,Zhang W,et al.Comparison of Percutaneous Coronary Intervention with Drug Eluting Stents Versus Coronary Artery Bypass Grafting in Patients With Multivessel Coronary Artery Disease:Meta-Analysis of Six Randomized Controlled Trials[J].Cardiovascular Revascularization Medicine,2015,15(1):70-77.
, http://www.100md.com
[6]Mieres J,Herscovich N,Rodríguez A E.Coronary Stenting Remains the First Revascularization Option in Most Patients with a Clinical Indication for Myocardial Revascularization[M].Controversies in Cardiology. Springer International Publishing,2015:187-201.
[7]Serruys P,Religa G,Ruzyllo W,et al.TCT-42 Long-term Safety and Efficacy of Percutaneous Coronary Intervention With Stenting and Coronary Artery Bypass Surgery for Left Main Disease: Final Five-year Follow-up of the SYNTAX Trial[J].Journal of the American College of Cardiology,2012,60(17):B13-B13.
, http://www.100md.com
[8]Alak A,Lugomirski P,Jolly S S.A Meta-Analysis of Randomized Controlled Trials of Everolimus-Eluting Stents Versus Bare-Metal Stents in Percutaneous Coronary Intervention[J].Canadian Journal of Cardiology,2013,29(10):S337.
[9]Fajadet J,Wijns W,Laarman G J,et al.Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study[J].Eurointervention Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology,2010,6(5):562.
, http://www.100md.com
[10]Onuma Y,Wykrzykowska J,Vranckx P,et al.Multivessel coronary revascularization in patients with and without diabetes mellitus 5-year follow-up of the ARTS-II trial[J].Journal of the American College of Cardiology,2010,55(10):A184.E1721-A184.E1721.
[11]Farooq V,van Klaveren D,Steyerberg EW,et al.Anatomical and clinical characteristic to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients:development and validation of SYNTAX score II[J].Lancet,2013, 381(9867):639-650.
, http://www.100md.com
[12]Mohr FW,Morice MC,Kappetein AP,et al.Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised,clinical SYNTAX trial[J].Lancet,2013,381(9867):629-638.
[13]中華医学会心血管病学分会介入心脏病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南(2016)[J].中华心血管病杂志,2016,44(5):382-400.编辑/成森, http://www.100md.com(曹静 孔祥 葛建军)
参考文献:
[1]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.中国心血管病预防指南[J].中华心血管病杂志,2011,39(1):3-22.
[2]Levine GN,Bates ER,Blankenship JC,et al.2015 AHA ACC SCAI focused update on primary percutaneous coronary intervention for patients with ST elevation myocardial infarction[J].Circulation,2016,133: 1135-1147.
[3]付焕梅.心血管病危险因素与冠脉病变支数关系的分析[J].中国心血管病研究,2010,8(1):36-39.
, 百拇医药
[4]Lee C W,Ahn J M,Cavalcante R,et al.Coronary Artery Bypass Surgery Versus Drug-Eluting Stent Implantation for Left Main or Multivessel Coronary Artery Disease:A Meta-Analysis of Individual Patient Data[J].Jacc Cardiovascular Interventions,2016:2481-2489.
[5]Fanari Z,Weiss S A,Zhang W,et al.Comparison of Percutaneous Coronary Intervention with Drug Eluting Stents Versus Coronary Artery Bypass Grafting in Patients With Multivessel Coronary Artery Disease:Meta-Analysis of Six Randomized Controlled Trials[J].Cardiovascular Revascularization Medicine,2015,15(1):70-77.
, http://www.100md.com
[6]Mieres J,Herscovich N,Rodríguez A E.Coronary Stenting Remains the First Revascularization Option in Most Patients with a Clinical Indication for Myocardial Revascularization[M].Controversies in Cardiology. Springer International Publishing,2015:187-201.
[7]Serruys P,Religa G,Ruzyllo W,et al.TCT-42 Long-term Safety and Efficacy of Percutaneous Coronary Intervention With Stenting and Coronary Artery Bypass Surgery for Left Main Disease: Final Five-year Follow-up of the SYNTAX Trial[J].Journal of the American College of Cardiology,2012,60(17):B13-B13.
, http://www.100md.com
[8]Alak A,Lugomirski P,Jolly S S.A Meta-Analysis of Randomized Controlled Trials of Everolimus-Eluting Stents Versus Bare-Metal Stents in Percutaneous Coronary Intervention[J].Canadian Journal of Cardiology,2013,29(10):S337.
[9]Fajadet J,Wijns W,Laarman G J,et al.Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study[J].Eurointervention Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology,2010,6(5):562.
, http://www.100md.com
[10]Onuma Y,Wykrzykowska J,Vranckx P,et al.Multivessel coronary revascularization in patients with and without diabetes mellitus 5-year follow-up of the ARTS-II trial[J].Journal of the American College of Cardiology,2010,55(10):A184.E1721-A184.E1721.
[11]Farooq V,van Klaveren D,Steyerberg EW,et al.Anatomical and clinical characteristic to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients:development and validation of SYNTAX score II[J].Lancet,2013, 381(9867):639-650.
, http://www.100md.com
[12]Mohr FW,Morice MC,Kappetein AP,et al.Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised,clinical SYNTAX trial[J].Lancet,2013,381(9867):629-638.
[13]中華医学会心血管病学分会介入心脏病学组,中国医师协会心血管内科医师分会血栓防治专业委员会,中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南(2016)[J].中华心血管病杂志,2016,44(5):382-400.编辑/成森, http://www.100md.com(曹静 孔祥 葛建军)
参见:首页 > 医疗版 > 疾病专题 > 心血管科 > 冠状动脉病 > 冠心病